Epicept Corp Sample Contracts

AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 14th, 2018 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of May 14, 2018, between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

ARTICLE I. DEFINITIONS
Securities Purchase Agreement • December 27th, 2006 • Epicept Corp • Pharmaceutical preparations • New York
RECITALS:
Indemnification Agreement • April 28th, 2005 • Epicept Corp • Pharmaceutical preparations • Delaware
IMMUNE PHARMACEUTICALS INC. UNDERWRITING AGREEMENT
Underwriting Agreement • October 16th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
5,500,000 Shares Common Stock ($0.0001 par value)
Underwriting Agreement • April 28th, 2005 • Epicept Corp • Pharmaceutical preparations • New York
BY AND AMONG
Note Purchase Agreement • November 1st, 2005 • Epicept Corp • Pharmaceutical preparations • Delaware
BETWEEN
Lease Agreement • January 10th, 2005 • Epicept Corp
ARTICLE I. DEFINITIONS
Securities Purchase Agreement • March 7th, 2008 • Epicept Corp • Pharmaceutical preparations • New York
ARTICLE I. DEFINITIONS
Securities Purchase Agreement • June 29th, 2007 • Epicept Corp • Pharmaceutical preparations • New York
WITNESSETH:
Employment Agreement • January 10th, 2005 • Epicept Corp • New Jersey
COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS, INC.
Immune Pharmaceuticals Inc • April 19th, 2017 • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, EMA Financial, LLC, a Delaware limited liability company (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 10, 2017 (as defined above) and on or prior to the close of business October 10, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from IMMUNE PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), up to 1,666,667 shares (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b), subject to adjustment herein. This Warrant is issued by the Company as of the date hereof in connection with the Purchase Agreement (as defined below).

COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC.
Common Stock Purchase Warrant • October 11th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cede & Co. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ], 2017 (the “Initial Exercise Date”) and on or prior to the close of business on the seven (7) year anniversary of the Initial Exercise Date (the “Termination Date”); provided, however, that if such date is not a Trading Day, the Termination Date shall be the immediately following Trading Day) but not thereafter, to subscribe for and purchase from Immune Pharmaceuticals Inc., a Delaware corporation (the “Company”), up to [_______] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security h

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 30th, 2011 • Epicept Corp • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2011, between EpiCept Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). Notwithstanding anything herein to the contrary regarding multiple Purchasers, the parties acknowledge and agree that the term “Purchaser” or “Purchasers” hereunder shall refer to only one institutional investor (and its Affiliates).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • September 18th, 2018 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 12, 2018, by and between Immune Pharmaceuticals Inc., a Delaware corporation, with its address at 550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ 07632 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).

Rodman & Renshaw
Epicept Corp • August 6th, 2008 • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE July 7, 2018
Immune Pharmaceuticals Inc • July 10th, 2017 • Pharmaceutical preparations • New York

THIS SENIOR SECURED CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued Senior Secured Convertible Notes of Immune Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ 07632, designated as its Senior Secured Convertible Promissory Note due July 7, 2018 (this “Note”, or the “Note” and collectively with the other Notes of such series, the “Notes”).

WITNESSETH:
Employment Agreement • January 10th, 2005 • Epicept Corp • New Jersey
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • November 22nd, 2016 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of November 17, 2016, between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, the “Purchasers” and each a “Purchaser”).

ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE
Immune Pharmaceuticals Inc • May 14th, 2018 • Pharmaceutical preparations • New York

THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Immune Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 550 Sylvan Avenue, Suite 101. Englewood Cliffs, NJ. 07632, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (as defined below) (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).

Immune Pharmaceuticals Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of October [ ], 2017 WARRANT AGENCY AGREEMENT
Warrant Agency Agreement • October 16th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York

WARRANT AGENCY AGREEMENT, dated as of October [ ], 2017 (“Agreement”), between Immune Pharmaceuticals Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a New York limited liability trust company (the “Warrant Agent”).

COMMON STOCK PURCHASE WARRANT
Common Stock Purchase • February 9th, 2012 • Epicept Corp • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from EpiCept Corporation, a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

RECITAL:
Sublicense Agreement • May 3rd, 2005 • Epicept Corp • Pharmaceutical preparations • Delaware
ARTICLE I. CERTAIN DEFINITIONS
Equity Distribution Agreement • December 27th, 2006 • Epicept Corp • Pharmaceutical preparations • New York
Time is Money Join Law Insider Premium to draft better contracts faster.